Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ConQuEST: N-803 in CRPC
NCT05445882Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Apr 2024
- Primary completion
- Apr 2024
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label trial of nogapendekin alfa inbakicept in castration-resistant prostate cancer (CRPC), sponsored by National Cancer Institute. Primary endpoint: Clinical Efficacy of N-803 alone or in combination at 12 weeks. Planned start Apr 2024; status: withdrawn.
02
Drugs
nogapendekin alfa inbakicept
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT05445882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05445882.